Liraglutide for diabetes and weight loss: what TikTok gets wrong

What's this video probably claiming?

Based on the hashtags and creator context, this video is likely a personal account of using liraglutide, the GLP-1 receptor agonist sold as Victoza (for type 2 diabetes) and Saxenda (for weight management). The creator, who identifies as a teacher, is probably sharing a first-person experience with the medication, possibly covering weight loss results, blood sugar management, or both. These "teacherlife" crossover videos tend to frame GLP-1 use as relatable and accessible, which can be refreshing, but they also tend to blur the line between anecdote and medical fact. The creator may be discussing dosing schedules, appetite suppression, or comparing liraglutide to the more heavily marketed semaglutide. Without the transcript, we can't confirm specifics, but the pattern is well-established: personal testimonials about GLP-1s almost always overclaim on speed of results and underclaim on side effect severity and discontinuation rates.

What does the science actually show?

Liraglutide has a real and documented evidence base, so let's be precise about what it actually does. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed that liraglutide at 3.0 mg daily produced a mean weight loss of 8.4 kg over 56 weeks, compared to 2.8 kg with placebo. That's meaningful but modest compared to the 15-17% body weight reductions now associated with semaglutide in the STEP trials. For diabetes, the LEAD trial program demonstrated HbA1c reductions of roughly 1.0-1.5% with liraglutide 1.8 mg, which is clinically useful. The LEADER trial (Marso et al., 2016, NEJM) also showed a 13% reduction in major cardiovascular events in high-risk type 2 diabetics, which is the drug's strongest selling point beyond glucose control. What TikTok rarely mentions: gastrointestinal side effects affected over 40% of participants in clinical trials, and discontinuation rates due to side effects in real-world use are substantially higher than trial conditions suggest.

Where does the social media noise diverge from clinical reality?

The biggest problem with liraglutide content on TikTok is context collapse. Victoza is a diabetes medication. Saxenda is a weight management medication. They contain the same molecule at different doses, but they are not interchangeable, and the regulatory distinction exists for real pharmacological and safety reasons. Creators routinely conflate them, which misleads viewers about what they might qualify for and why. There's also a tendency to present liraglutide as a "starter" GLP-1 before graduating to semaglutide or tirzepatide, framing it like a stepwise self-upgrade program. That's not how this works clinically. Second, liraglutide requires daily injections versus semaglutide's weekly dosing, and real-world adherence data show that matters significantly for outcomes. A 2022 analysis in Diabetes, Obesity and Metabolism (Wilding et al.) found that persistence rates for daily GLP-1 injectables drop sharply after six months. Sharing one person's positive three-month snapshot without that context is incomplete at best.

What should you actually know?

If you're considering liraglutide after watching videos like this, a few things are worth understanding clearly. First, insurance coverage for Saxenda is inconsistent and often requires documented obesity-related comorbidities and prior authorization, regardless of what TikTok makes it sound like. Second, the weight loss results seen in clinical trials were achieved alongside structured diet and exercise intervention, not medication alone. Third, compounded liraglutide is not the same product as FDA-approved Victoza or Saxenda. Compounded versions lack the same purity and stability testing, and no clinical trial data support their use. The FDA has noted concerns about compounded GLP-1 products broadly. Fourth, stopping liraglutide typically results in weight regain. Data from the SCALE Maintenance trial (Wadden et al., 2013, Obesity) showed that participants who discontinued the drug regained a significant portion of lost weight within 12 weeks. Any video framing liraglutide as a short-term fix is working against the actual clinical picture.